Newron Pharmaceuticals Raises EUR 30 Million
Newron Pharmaceuticals SpA, a research and development company focused on novel CNS therapies, announced the raising of EUR 30 million (fully committed), out of which EUR 23 million closed already. The remaining EUR 7 million will remain open to additional interested parties for a few weeks. HBM Partners AG, on behalf of HBM BioCapital L.P. and HBM BioVentures (Cayman) Ltd., acted as lead investor. Existing investors, 3i Group, Apax Partners and Atlas Venture have all participated in the round.
Newron will use the proceeds of the financing primarily to further advance the worldwide Phase III development of Safinamide for Parkinson's disease as well as preparing to move the compound forward in other indications. In addition, the funds will be used to progress the development of the neuropathic pain project currently in phase II and the preclinical stage compounds through clinical trials.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.